Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deregulation of HLA-I in cancer and its central importance for immunotherapy

1 Aug 2021

Abstract excerpt

It is now well accepted that many tumors undergo a process of clonal selection which means that tumor antigens arising at various stages of tumor progression are likely to be represented in just a subset of tumor cells. This process is thought to be driven by constant immunosurveillance which applies selective pressure by eliminating tumor cells expressing antigens that are recognized by T cells. It is becoming...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34353849
DOI: 10.1136/jitc-2021-002899

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deregulation of HLA-I in cancer and its central importance for immunotherapyPMID 34353849Read ↗

Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms.Semantic proximity Read ↗

Role of altered expression of HLA class I molecules in cancer progression.Semantic proximity Read ↗

Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer PatientsSemantic proximity Read ↗

Assessment of cancer cell‐expressed HLA class I molecules and their immunopathological implicationsSemantic proximity Read ↗

The HLA crossroad in tumor immunology.Semantic proximity Read ↗

HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activationSemantic proximity Read ↗

Targeting HLA class I expression to increase tumor immunogenicitySemantic proximity Read ↗

The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses.Semantic proximity Read ↗

Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.Semantic proximity Read ↗

Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyondSemantic proximity Read ↗

Different mechanisms can lead to the same altered HLA class I phenotype in tumors.Semantic proximity Read ↗

Human Leukocyte Antigen–G and Cancer ImmunoeditingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.